CytoDyn (STU:296) Tariff Resilience Score: 8/10 (As of Jul. 08, 2026)


STU:296 CytoDyn Inc STU:296
27 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is CytoDyn Tariff Resilience Score?

CytoDyn STU:296 -25.58% 27 Tariff Resilience Score is 8 as of Jul. 08, 2026. GuruFocus rates STU:296 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,367 Biotechnology companies, CytoDyn ranks better than 98.68% on this metric.

CytoDyn has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

CytoDyn has CytoDyn, a biotech company, has limited exposure to tariffs due to its focus on pharmaceuticals, which are often exempt from tariffs. Its supply chain is not heavily reliant on international manufacturing, providing a buffer against trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CytoDyn might have Highly Resilient.

CytoDyn  (STU:296) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CytoDyn Tariff Resilience Score Related Terms

STU:296 vs VSTM, IRD, PALI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CytoDyn's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CytoDyn's Tariff Resilience Score falls into.


STU:296
27GF Score
CytoDyn Inc STU:296
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
CytoDyn (STU:296) has a Tariff Resilience Score of 8 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CytoDyn ranks #18 out of 1367 companies in the Biotechnology industry, placing it in the top 1.3%.
Is CytoDyn's Tariff Resilience Score too high?
CytoDyn's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. CytoDyn's value of 8 is 100% above this industry median. Based on the distribution chart, CytoDyn ranks #18 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytoDyn has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Tariff Resilience Score compare to VSTM and IRD?
According to the Biotechnology industry distribution chart, CytoDyn ranks #18 out of 1367 companies for Tariff Resilience Score. This places CytoDyn in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CytoDyn's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoDyn's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. CytoDyn's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CytoDyn (STU:296), the current Tariff Resilience Score is 8 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
27GF Score

Get the complete analysis for STU:296

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price